BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High – Should You Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $9.40 and last traded at $9.36, with a volume of 600478 shares. The stock had previously closed at $9.05.

Analysts Set New Price Targets

BCRX has been the subject of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $15.50.

BioCryst Pharmaceuticals Price Performance

The company has a market cap of $1.94 billion, a price-to-earnings ratio of -15.32 and a beta of 1.75. The business’s fifty day moving average price is $7.89 and its 200 day moving average price is $7.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in BioCryst Pharmaceuticals by 3.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after buying an additional 11,581 shares during the last quarter. Woodline Partners LP bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $3,385,000. Two Sigma Advisers LP boosted its position in shares of BioCryst Pharmaceuticals by 14.6% during the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after purchasing an additional 318,800 shares in the last quarter. Two Sigma Investments LP grew its stake in BioCryst Pharmaceuticals by 0.8% during the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company’s stock worth $13,342,000 after purchasing an additional 13,406 shares during the period. Finally, Sherbrooke Park Advisers LLC increased its holdings in BioCryst Pharmaceuticals by 25.9% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,628 shares of the biotechnology company’s stock worth $260,000 after purchasing an additional 7,134 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.